投资策划网—规模最大、实力最强的研究报告提供商! 关于我们 联系中撰 网站地图
稳评报告
当前位置:主页 > 稳评报告 > >> China Heparin Industry Report, 2012-2016
China Heparin Industry Report, 2012-2016
2012-02-07 16:19共有人浏览
更多
内 容
 

报告名称:China Heparin Industry Report, 2012-2016
编撰机构:广州中撰企业投资咨询有限公司
出版日期:2011年12月
报告页码:177页,图表149个
交付方式:EMAIL电子版或特快专递
中文版价格:印刷版:RMB 7600 电子版:RMB 8100 印刷版+电子版:RMB 8600
英文版价格:印刷版:USD 4800 电子版:USD 4800 印刷版+电子版:USD 4900
订购电话:(0086)020-66699282、15989039303
联 系 人:余先生、方小姐
客 服 QQ:1767696378(全天24小时)

 

 

【Abstract】:
  
With richness in heparin materials and the quality of heparin API getting accredited by the international community, China has become one of the largest heparin API producers and exporters in the world. In 2010, there were 24 heparin API manufacturers with the heparin sodium API production license granted by SFDA in China, with the export volume of heparin API reaching 15.9 trillion units, a 52.1% market share globally.

Europe and America are the major export destinations of heparin API made in China. From January to July of 2011, heparin and heparinate made in China were exported to 44 countries. In terms of export volume, the top 5 export destinations were France, Germany, America, Austria and Italy, with the combined export volume standing at 83.7%.

It is required to obtain CEP certification of EU or FDA authentication of the US for companies to access into the European and American markets. Due to the stringent authentication criterion, many unqualified enterprises are forced to withdraw from the market. As of August, 2011, China had 6 CEP certified heparin API producers and 2 FDA certified ones. In particular, both Shenzhen Hepalink Pharmaceutical     and Changzhou Qianhong Bio-Pharma obtained the two certifications, an edge over the oppositions.

Although it is a large producer of heparin API, the production of downstream unfractionated heparin (UFH) sodium preparations and low-molecular-weight (LMW) heparin preparations in China is still in its infancy.

In the UFH preparation market, 26 Chinese companies have obtained the heparin sodium injection drug production licenses granted by SFDA. Due to the mounting pressure arising from the soaring price of heparin API, there are less than 10 companies that seem competitive in Chinese market, such as Tianjin Biochemical Pharmaceutical, Wanbang Biopharmaceuticals and Shanghai No.1 Chemical & Pharmaceutical, but all of them need to procure upstream raw material for production.

Restricted by the technology, the LMW heparin preparation market of China is dominated by foreign brands. In 2009, Chinese markets of LMW heparin sodium and LMW heparin calcium were dominated by France-based Sanofi’s Clexane and GSK’s Fraxiparine, topping the market with the respective share of 54.5% and 59.0%. However, the LMW heparin preparation products made by domestic companies become increasingly competitive with the enhanced strength in R&D and technology. For instance, the sales of Hebei Changshan Biochemical Pharmaceutical, a company producing LMW heparin calcium injection, rose 72.6% YoY to RMB51.612 million in 2010.


【Table of Contents】 

1. Profile of Heparin Industry 
1.1 Definition & Classification 
1.2 Industry Chain

2. International Operating Environment of Heparin Industry 
2.1 Demand of Heparin Medicine 
2.2 Distribution of Heparin Medicine Demand 
2.3 Heparin API Demand 
2.4 Overseas Competitors 
2.5 Related Policies 
2.6 Market Forecast

3. Current Development of China Heparin API Industry 
3.1 Market Overview 
3.2 Demand & Supply 
3.3 Competition
3.4 Dynamics 
3.5 Related Policies 
3.6 Market Forecast

4. Current Development of China Heparin Preparation Industry 
4.1 Overview of Antithrombotic Drugs 
4.2 Market Overview 
4.3 UFH Preparations 
4.3.1 International Environment
4.3.2 Market Size
4.3.3 Competition
4.4 LMW Heparin Preparations 
4.4.1 International Environment 
4.4.2 Market Size
4.5 Demand & Supply 
4.6 Competition
4.7 Dynamics & Patents 
4.8 Market Forecast 
5. Import & Export 
5.1 Export 
5.1.1 Export Volume
5.1.2 Export Destinations 
5.2 Import 
5.2.1 Import Destinations 
5.2.2 Import Origins

6. Heparin Manufacturers in China 
6.1 Shenzhen Hepalink Pharmaceutical 
6.1.1 Profile 
6.1.2 Operation 
6.1.3 Dynamics 
6.2 Changzhou Qianhong Bio-Pharma Co., Ltd 
6.2.1 Profile 
6.2.2 Operation 
6.2.3 Dynamics 
6.3 Tianjin Chase Sun Pharmaceutical 
6.3.1 Profile 
6.3.2 Operation 
6.3.3 Dynamics 
6.4 Hebei Changshan Biochemical Pharmaceutical 
6.4.1 Profile 
6.4.2 Operation 
6.4.3 Dynamics 
6.5 Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd 
6.5.1 Profile 
6.5.2 Operation 
6.6 Yantai Dongcheng Biochemicals Co., Ltd 
6.6.1 Profile 
6.6.2 Operation 
6.7 Wanbang Biopharmaceuticals 
6.7.1 Profile 
6.7.2 Operation 
6.7.3 Dynamics


【Figures & Tables】

Application of Heparin Preparations
Heparin Industry Chain 
Sales of Heparin Drugs Worldwide, 2003-2012E  
Distribution of Heparin Drug Consumption Worldwide, 2010 
Market Size and Growth Rate of Heparin API Worldwide,2007-2013
Forecast of Global Heparin Drug Market Development  
Export Volume and The Global Proportion of Heparin API in China, 
2007-2010
Number of Slaughtered Fattened Hogs (Head) and Year-end Number of 
Hogs (Head) of China, 2003-2010  
Price Trend of Crude Sodium Heparin API in China, 2008-2010  
Top ten Pharmaceutical Companies by Export Value of Heparin in 
China, Jan.-Sep.2010
Gross Margin of Major Heparin API Manufacturers in China, 2008-2010
Heparin Sodium API Supply in China and the World and China’s Share, 
2011-2013 
China Antithrombotic Drug Market Size, 2003-2012 
Market Share of China's Major Varieties of Anti-thrombosis Drug in 
Hospital,2005-2009 
Market Size of Heparin Drug in China,2007-2013
Chinese Market Share of Heparin Preparation Products, 2009 
Market Size of Global UFH Preparations,2006-2012 
Sales of UFH Preparations in China,2006-2012
Market Demand for Heparin Sodium Injection Solution in China, 
2007-2012  
Manufacturers of Heparin Sodium Injection Solution and Heparin 
Calcium Injection Solution in China 
Operation of Major UFH Preparations,Manufacturers in China,2008-2009
Performance Comparison between Low Molecular Weight Heparin 
Preparations and UFH Preparations
Market Size of Global Low Molecular Weight Heparin 
Preparations,2006-2012
Market Size of Low Molecular Weight Heparin Preparations in 
China,2006-2010
Proportion of Low-molecular Heparin Calcium and Low-molecular 
Heparin Sodium in Anticoagulant Medicines of China, 2005-2011 
Manufacturers of Low-molecular Heparin Sodium Preparations and 
Low-molecular Heparin Calcium Preparations
Competition Pattern of China Low-Molecular-Weight Heparin Sodium 
Market, 2009 
YoY Growth Rate for Sales of Main Competitive Enterprises of 
Low-molecular Weight Heparin Sodium in China, 2009 
Competition Pattern of China Low-Molecular-Weight Heparin Calcium 
Market, 2009 
YoY Growth Rate for Sales of Main Competitive Enterprises of 
Low-molecular Weight Heparin Calcium in China, 2009 
Main Patents for LMW Heparin 
China LMW Heparin Drug Market Size, 2010-2014 
Export of Key Western Medicines of China, Jan.-Jul. 2011 
Export Value and Its Growth Rate of Heparin and Its Salts in 
China,2008-2011
China’s Export Volume and Price Trend of Heparin Products, 2008-2011

Overseas Market Distribution of Heparin Products in China, 
Jan.-Jul.2011
Main Chinese Exporting Enterprises of Heparin API and Their 
Percentages by Export Value, Jan.-Sep., 2009 and Jan.-Sep., 2010 
Import Volume and Unit Price Trend of Heparin Products in China, 
2008-Jan-Jul.2011 
Destinations of China’s Heparin Product Imports, 2008- Jan-Jul.2011 
Import Origins of China Heparin Products, 2008- Jan-Jul.2011 
Heparin Sodium API Operating Revenue and YOY of Shenzhen Hepalink 
Pharmaceutical Co., Ltd., 2007- H1 2011 
Heparin Sodium API Revenue of Shenzhen Hepalink Pharmaceutical Co., 
Ltd by Product Grade, 2007- H1 2011 
Gross Margin of Heparin API (by Product) of Shenzhen Hepalink 
Pharmaceutical Co., Ltd., H12007-2011
Operating Revenue of Shenzhen Hepalink Pharmaceutical Co., Ltd. by 
Region, 2007- H1 2011
Total Profit and YPY of Shenzhen Hepalink Pharmaceutical Co., Ltd., 
2007- H1 2011 
Operating Revenue and Net Income of Changzhou Qianhong Bio-Pharma 
Co., Ltd., 2007- H1 2011
Operating Revenue (by Product ) of Changzhou Qianhong Bio-Pharma 
Co., Ltd., 2008- H1 2011
Gross Margin (by Product ) of Changzhou Qianhong Bio-Pharma Co., 
Ltd., 2009- H1 2011
Operating Revenue of Changzhou Qianhong Bio-Pharma Co., Ltd. by 
Region,2007- H1 2011
Top Five Clients of Heparin Sodium API of Changzhou Qianhong 
Bio-Pharma Co., Ltd, 2009-2010 
R&D Input and Its Ratio to Operating Revenue of Changzhou Qianhong 
Bio-Pharma Co., Ltd, 2008-2010
Operating Revenue and Net Income of Tianjin Chase Sun Pharmaceutical 
Co., Ltd., 2007- H1 2011 
Operating Revenue (by Product) of Tianjin Chase Sun Pharmaceutical 
Co., Ltd, 2009 - H1 2011 
Gross Margin (by Product ) of Tianjin Chase Sun Pharmaceutical Co., 
Ltd, 2008- H1 2011
Heparin Calcium Operating Revenue and YoY Growth of Tianjin Chase 
Sun Pharmaceutical Co., Ltd, 2007- H1 2011 
Operating Revenue of Tianjin Chase Sun Pharmaceutical Co., Ltd. by 
Region, 2008-2011H1 Competition and Distribution of Major Businesses 
of Tianjin Chase Sun Pharmaceutical Co., Ltd.
Operating Revenue and Net Income of Hebei Changshan Biochemical 
Pharmaceutical Co., Ltd, 2008-2010 
Operating Revenue (by Product) of Hebei Changshan Biochemical 
Pharmaceutical Co.,Ltd., 2008-2010
Gross Margin (by Product ) of Hebei Changshan Biochemical 
Pharmaceutical Co.,Ltd., 2008-2010
Operating Revenue of Hebei Changshan Biochemical Pharmaceutical Co., 
Ltd. by Region, 2008-2010 
Sales of Top Five Customers of Hebei Changshan Biochemical 
Pharmaceutical Co., Ltd. and Their Proportion to total Operating 
Revenue,2008-2010 
R&D Input and Its Ratio to Operating Revenue of Hebei Changshan 
Biochemical Pharmaceutical Co.,Ltd.,2008-2010
Projects under R&D and Expected Target of Changshan Biochemical 
Pharmaceutical Co., Ltd. 
Raising Project of Changshan Biochemical Pharmaceutical Co.,Ltd.
Heparin API Export of Nanjing King-Friend Biochemical Pharmaceutical 
Co., Ltd., Jan.-Sep., 2009 and Jan.-Sep., 2010 
Operation of Nanjing King-Friend Biochemical Pharmaceutical Co., 
Ltd, 2008-2009 
Operation of Yantai Dongcheng Biochemicals Co., Ltd, 2008-2009  
Heparin API Export of Yantai Dongcheng Biochemicals Co., Ltd, 
Jan.-Sep., 2009 and Jan.-Sep., 2010 
Operation of Wanbang Biopharmaceuticals, 2008-2009 


【编辑:中国投资政策网】 TOP
专项定制报告专项定制报告分类
专项报告类别:
商业计划书 | 可行性研究报告 | 资金申请报告
可行性报告 | 项目申请报告 | 英文报告
联系方式
·联系人:
余先生、方小姐
·电话号码:
15989039303
·地址:
广州市番禺区桥南街福德路241号奥园广场塔三1305室

订购流程订购流程
① 签订可行性报告订购合同;
② 通过银行转帐、邮局汇款等形式款项;
③ 中国投资策划网见到汇款底单或者转帐底单后,24小时内发送可行性研究报告电子版,72小时内寄送正式版以及发票。